A Prospective Observational Study in Nivolumab Therapy for Advanced or Recurrent Esophageal Squamous Cell Carcinoma after Cancer Chemotherapy
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ANTARES study
- 21 Feb 2022 Status changed from not yet recruiting to recruiting.
- 25 Mar 2021 New trial record